Role of hematopoietic stem cell transplant in the management of follicular lymphoma

Oncologist

Volumn 14, Issue 7, 2009, Pages 726-738

  Foster, Matthew ^a,b   Gabriel, Don A ^a   Shea, Thomas ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bone marrow purging; Follicular lymphoma; Hematopoietic stem cell transplantation; Lymphoma; Non Hodgkin's; Rituximab; Transplantation conditioning

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; INTERFERON; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TENIPOSIDE; VINCRISTINE; VINDESINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; TRANSPLANTATION CONDITIONING;

EID: 68449088401     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0045     Document Type: Review

References (73)

1. Johnson PW, Rohatiner AZ, Whelan JS et al. Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 1995;13:140-147.
2. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20(suppl 5):75-88. (Pubitemid 23319044)
3. Fisher RI, LeBlanc M, PressOWet al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23: 8447-8452. (Pubitemid 46260240)
4. Swenson WT, Wooldridge JE, Lynch CF et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019-5026. (Pubitemid 46224008)
5. Schouten HC, Bierman PJ, Vaughan WP et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 1989;74:2579-2584. (Pubitemid 19286482)
6. van Besien K, Loberiza FR Jr, Bajorunaite R et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003;102:3521-3529. (Pubitemid 37409366)
7. Ramadan KM, Connors JM, Al-Tourah A et al. Salvage therapy with allogeneic stem cell transplantation results in better outcome for patients with relapsed/refractory follicular lymphoma compared to those with transformed non-Hodgkin lymphoma: A population-based comparative study- [abstract 975]. Blood 2008;112:359.
8. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-1423. (Pubitemid 40223656)
9. Fisher RI, Kaminski MS, Wahl RL et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565-7573.
10. Witzig TE, Molina A, Gordon LI et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007;109:1804-1810. (Pubitemid 46668544)
11. van Besien K, Sobocinski KA, Rowlings PA et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998;92:1832-1836. (Pubitemid 28406891)
12. Hari P, Carreras J, Zhang MJ et al. Allogeneic transplants in follicular lymphoma: Higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14:236-245.
13. Vigouroux S, Michallet M, Porcher R et al. Long-term outcomes after reduced- intensity conditioning allogeneic stem cell transplantation for lowgrade lymphoma: A survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007; 92:627-634. (Pubitemid 350147794)
14. Brown JR, Feng Y, Gribben JG et al. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007;13:1057-1065. (Pubitemid 47224617)
15. Lenz G, Dreyling M, Schiegnitz E et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004;22:4926-4933. (Pubitemid 46638617)
16. Rohatiner AZ, Nadler L, Davies AJ et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: Long-term follow-up. J Clin Oncol 2007;25:2554-2559. (Pubitemid 47044812)
17. Baker KS, DeFor TE, Burns LJ et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: Incidence and risk factors. J Clin Oncol 2003;21:1352-1358.
18. Bhatia S, Louie AD, Bhatia R et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001;19:464-471. (Pubitemid 32112860)
19. Laudi N, Arora M, Burns LJ et al. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005;11:129-135. (Pubitemid 40186210)
20. Sacchi S, Marcheselli L, Bari A et al. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study. Haematologica 2008;93:398-404.
21. Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999;94:3325-3333. (Pubitemid 29536125)
22. Montoto S, Canals C, Rohatiner AZ et al. Long-term follow-up of highdose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: AnEBMTregistry study. Leukemia 2007;21:2324-2331. (Pubitemid 350011705)
23. Tarella C, Corradini P, Astolfi M et al. Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: Evidence for longterm clinical and molecular remissions. Leukemia 1999;13:1456-1462. (Pubitemid 29429775)
24. Khouri IF, Bassett R, Samuels B et al. Addition of rituximab to mobilization and conditioning overcomes the predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) score in patients with relapsed FL undergoing autologous stem cell transplantation (AUTO)[abstract 1140]. Blood 2008;112:416.
25. Arcaini L, Montanari F, Alessandrino EP et al. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol 2008;19:1331-1335. (Pubitemid 351911967)
26. Tarella C, Zanni M, Magni M et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma:Amulticenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol 2008;26:3166-3175.
27. van Heeckeren WJ, Vollweiler J, Fu P et al. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: In vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device. Br J Haematol 2006;132:42-55.
28. Altès A, Sierra J, Esteve J et al. CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: High purging efficiency but increased risk of severe infections. Exp Hematol 2002;30:824-830. (Pubitemid 34831704)
29. Crippa F, Holmberg L, Carter RA et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2002;8:281-289. (Pubitemid 34619080)
30. Schouten HC, Qian W, Kvaloy S et al. High-dose therapy improves progression- free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial. J Clin Oncol 2003;21:3918-3927. (Pubitemid 46606204)
31. Lenz G, Dreyling M, Schiegnitz E et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004;104:2667-2674. (Pubitemid 39434946)
32. Gyan E, Foussard C, Bertrand P et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by the GOELAMS with final results after a median follow- up of 9 years. Blood 2009;113:995-1001.
33. Sebban C, Mounier N, Brousse N et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006;108:2540-2544. (Pubitemid 44776986)
34. Howe R, Micallef IN, Inwards DJ et al. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 2003;32:317-324. (Pubitemid 36927085)
35. Micallef IN, Lillington DM, Apostolidis J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000;18:947-955. (Pubitemid 30123769)
36. van Oers MH, Klasa R, Marcus RE et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-3301. (Pubitemid 44794222)
37. Hoerr AL, Gao F, Hidalgo J et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2004;22:4561-4566. (Pubitemid 41185123)
38. Kang TY, Rybicki LA, Bolwell BJ et al. Effect of prior rituximab on highdose therapy and autologous stem cell transplantation in follicular lymphoma. Bone Marrow Transplant 2007;40:973-978. (Pubitemid 350048196)
39. Sebban C, Brice P, Delarue R et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: A GELA study. J Clin Oncol 2008;26:3614-3620.
40. Hiddemann W, Buske C, KnebaMet al. Autologous stem cell transplantation after myeloablative therapy in first remission may be beneficial in patients with advanced stage follicular lymphoma after front-line therapy with R-CHOP. An analysis of two consecutive studies of the German Low Grade Lymphoma Study Group (GLSG)[abstract 772]. Blood 2008;112: 286-287.
41. Buske C, Hoster E, DreylingMet al. Rituximab in combination with CHOP in patients with follicular lymphoma: Analysis of treatment outcome of 552 patients treated in a randomized trial of the German Low Grade Lymphoma Study Group (GLSG) after a follow up of 58 months[abstract 2599]. Blood 2008;112:901.
42. Ladetto M, De Marco F, Benedetti F et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008;111:4004-4013.
43. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
44. Federico M, Vitolo U, Zinzani PL et al. Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000;95:783-789.
45. Verdonck LF, Dekker AW, Lokhorst HM et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997;90:4201-4205. (Pubitemid 27484077)
46. Mandigers CM, Verdonck LF, Meijerink JP et al. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 2003;32: 1159-1163.
47. van Besien KW, de Lima M, Giralt SA et al. Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versuslymphoma effect. Bone Marrow Transplant 1997;19:977-982.
48. Bierman PJ, Sweetenham JW, Loberiza FR Jr et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: A comparison with allogeneic and autologous transplantation-the Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003;21:3744-3753.
49. Laport G, Bredeson CN, Tomblyn M et al. Autologous versus reducedintensity allogeneic hematopoietic cell transplantation for patients with follicular non-Hodgkin's lymphoma (FL) beyond first complete response or first partial response[abstract 7041]. J Clin Oncol 2008;26:382s.
50. Robinson S, Canals C, Blaise D et al. Reduced-intensity allogeneic stem cell transplantation for follicular lymphoma results in an improved progression free survival when compared to autologous stem cell transplantation. An analysis from the Lymphoma Working Party of the EBMT[abstract 458]. Blood 2008;112:175.
51. Ingram W, Devereux S, Das-Gupta EP et al. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol 2008;141:235-243.
52. Sureda A, Avivi I, Canals C et al. Impact of the intensity of conditioning regimen in 144 patients with follicular lymphoma (FL) receiving a matched unrelated donor stem cell transplant (MUD-SCT): An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (LWP-EBMT)[abstract 7036]. J Clin Oncol 2008;26:381s.
53. Nagler A, Slavin S, Varadi G et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000;25:1021-1028. (Pubitemid 30303589)
54. Robinson SP, Goldstone AH, Mackinnon S et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310-4316. (Pubitemid 35429668)
55. Kusumi E, Kami M, Kanda Y et al. Reduced-intensity hematopoietic stemcell transplantation for malignant lymphoma:Aretrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 2005;36:205-213. (Pubitemid 41136292)
56. Rezvani AR, Storer B, Maris M et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008;26:211-217.
57. Khouri IF, McLaughlin P, Saliba RM et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008;111:5530-5536.
58. Shea TC, Johnston J, Walsh W et al. Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients (Pts) with advanced indolent NHL and CLL: CALGB 109901[abstract 486]. Blood 2007;110:150a.
59. Morris E, Thomson K, Craddock C et al. Outcomes after alemtuzumabcontaining reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004;104:3865-3871. (Pubitemid 39620131)
60. Rodriguez R, Nademanee A, Ruel N et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006;12:1326-1334. (Pubitemid 44858267)
61. Tomblyn M, Brunstein C, Burns LJ et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008;14:538-545.
62. Sorror ML, Storer BE, Maloney DG et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008;111:446-452.
63. Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912-2919. (Pubitemid 41510773)
64. Rodrigues C, Sanz G, Brunstein C et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies-A Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation study. Presented at the 34th Annual Meeting of the European Group for Blood and Marrow Transplantation, Florence, Italy, March 30-April 2, 2008.
65. Lekakis L, Giralt S, Couriel D et al. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant 2006;38:421-426. (Pubitemid 44340372)
66. Krishnan A, Nademanee A, Fung HC et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008;26:90-95.
67. Nademanee A, Forman S, Molina A et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005; 106:2896-2902. (Pubitemid 41510771)
68. Nademanee AP, Krishnan A, Tsai N et al. 90Y-ibritumomab tiuxetan (Zevalin) in combination with high-dose therapy (HDT) followed by autologous stem cell transplant (ASCT) may improve survival in patients with poor-risk follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL): Results of a retrospective comparative analysis[abstract 327]. Blood 2006;108:102a.
69. Bethge WA, Lange T, von Harsdorf S et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced indolent non-Hodgkin lymphoma: Interim analysis of a phase II study[abstract 1959]. Blood 2008;112:684.
70. Gopal AK, Rajendran JG, Gooley TA et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007;25:1396-1402.
71. Gopal AK, Gooley TA, Maloney DG et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariable cohort analysis. Blood 2003;102:2351-2357.
72. Sorror M, Storer B, Sandmaier BM et al. Hematopoietic cell transplantation- comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008;112:1992-2001. (Pubitemid 351574075)
73. Solal-Céligny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265. (Pubitemid 39166497)